Search

Search Constraints

You searched for: Author/Creator Heymach, J.

Search Results

1. A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL. (December 2016)

2. A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations. (October 2022)

3. G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. (December 2016)

4. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. (27th September 2016)